JP2024527380A5 - - Google Patents
Info
- Publication number
- JP2024527380A5 JP2024527380A5 JP2024501166A JP2024501166A JP2024527380A5 JP 2024527380 A5 JP2024527380 A5 JP 2024527380A5 JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024527380 A5 JP2024527380 A5 JP 2024527380A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- rnai
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220400P | 2021-07-09 | 2021-07-09 | |
| US63/220,400 | 2021-07-09 | ||
| PCT/IB2022/056278 WO2023281434A1 (en) | 2021-07-09 | 2022-07-07 | Use of oligonucleotides for individuals with renal impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527380A JP2024527380A (ja) | 2024-07-24 |
| JP2024527380A5 true JP2024527380A5 (https=) | 2025-07-08 |
Family
ID=82703082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501166A Pending JP2024527380A (ja) | 2021-07-09 | 2022-07-07 | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240336921A1 (https=) |
| EP (1) | EP4367241A1 (https=) |
| JP (1) | JP2024527380A (https=) |
| CN (1) | CN117616121A (https=) |
| CA (1) | CA3224600A1 (https=) |
| TW (1) | TW202323525A (https=) |
| WO (1) | WO2023281434A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| BR0314236A (pt) | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| BR112013003875B1 (pt) | 2010-08-20 | 2021-10-05 | Replicor Inc | Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| CN106659730A (zh) | 2014-07-10 | 2017-05-10 | 里普利科股份有限公司 | 治疗b型肝炎和d型肝炎病毒感染的方法 |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| PE20211783A1 (es) | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
| WO2020163747A1 (en) * | 2019-02-07 | 2020-08-13 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for hepatitis b virus infection |
| CA3132170A1 (en) * | 2019-04-18 | 2020-10-22 | Michael BIERMER | Combination therapy for treating hepatitis b virus infection |
| US20200332297A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
-
2022
- 2022-07-07 JP JP2024501166A patent/JP2024527380A/ja active Pending
- 2022-07-07 CA CA3224600A patent/CA3224600A1/en active Pending
- 2022-07-07 CN CN202280048358.4A patent/CN117616121A/zh active Pending
- 2022-07-07 WO PCT/IB2022/056278 patent/WO2023281434A1/en not_active Ceased
- 2022-07-07 US US18/577,450 patent/US20240336921A1/en active Pending
- 2022-07-07 EP EP22747759.3A patent/EP4367241A1/en active Pending
- 2022-07-08 TW TW111125691A patent/TW202323525A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI761311B (zh) | 拮抗ｂ型肝炎病毒之組成物和藥劑及彼等之用途 | |
| TWI872048B (zh) | 用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑 | |
| TWI702045B (zh) | 治療甲狀腺素運載蛋白（ｔｔｒ）調節之澱粉樣變性的方法 | |
| JP2024153797A5 (https=) | ||
| FI3837366T3 (fi) | Hepatiitti b -viruksen (hbv) dsrna-ainekoostumuksia ja niiden käyttömenetelmiä | |
| JP6922030B2 (ja) | Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 | |
| US20240052350A1 (en) | Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus | |
| TW202334420A (zh) | 用於Ｂ型肝炎病毒感染之ＲＮＡｉ藥劑 | |
| JP2022515778A5 (https=) | ||
| US11685921B2 (en) | Molecules and agents for treating hepatitis B virus | |
| JP2025096283A5 (https=) | ||
| JP2024544532A5 (https=) | ||
| US20250263705A2 (en) | Pharmaceutical combinations for treatment of hbv | |
| JP2024527380A5 (https=) | ||
| WO2010008474A4 (en) | Methods for treating multiple sclerosis using antisense oligonucleotides | |
| CN114057816B (zh) | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 | |
| JP7376679B2 (ja) | Ｈｂｖ感染の処置のためのｅｙｐ００１とｉｆｎの相乗効果 | |
| JP2024528659A5 (https=) | ||
| HK40092095A (zh) | 一种用於预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒 |